Physician profile
Gordon Lui
NPI 1356381974
$2,203.70
in general payments reported to CMS, 2019-2025
26 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $117 · 2021: $357 · 2022: $319 · 2023: $349 · 2024: $396 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $309.62 | 2022-2025 | Vyzulta, Miebo, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $303.71 | 2019-2021 | |
| Alcon Vision LLC | $205.93 | 2019-2025 | Argos, Tryptyr, Clareon |
| Oyster Point Pharma, INC. | $156.17 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $144.51 | 2019-2023 | |
| Abbvie INC. | $131.11 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $124.53 | 2023-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $107.92 | 2020-2023 | Cequa |
| Horizon Therapeutics Plc | $98.69 | 2021-2023 | Tepezza |
| Ocular Therapeutix, INC. | $95.00 | 2025 | Dextenza |
| Allergan, INC. | $82.57 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $73.46 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $62.11 | 2019 | |
| Harrow Eye, LLC | $45.35 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $37.92 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $26.58 | 2025 | Syfovre |
| Rxsight INC | $25.82 | 2021 | |
| Thea Pharma INC. | $24.93 | 2025 | Iyuzeh |
| Glaxosmithkline, LLC. | $23.86 | 2025 | Blenrep |
| Amgen INC. | $23.44 | 2025 | Tepezza |
| Sight Sciences, INC. | $19.19 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $18.65 | 2019 | |
| Alcon Research LLC | $18.45 | 2019 | |
| Dompe US, INC. | $18.23 | 2019 | |
| Coopervision INC. | $14.79 | 2024 | Misight Contact Lens |
| Aerie Pharmaceuticals, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Lui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.